Galidesivir (BCX4430) hydrochloride is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir hydrochloride has demonstrated pronounced efficacy[1].
Galidesivir hydrochloride (4 mg/kg; i.p.; twice daily for 7 days) is effectively in a hamster model of yellow fever (YF)[4].
| Animal Model: | Female Syrian golden hamsters (hamsters infected with YF virus)[4] |
| Dosage: | 4 mg/kg of body weight |
| Administration: | I.p.; twice daily for 7 days |
| Result: | Significantly improved the survival of hamsters infected with YFV. |